RT期刊文章SR电子T1的分析疾病活动返回natalizumab撤军后多发性硬化症(p3.2 - 069)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP p3.2补充92 - 069签证官是15 A1 Luna Fuentes鲁米A1首页何塞玛丽亚卡布瑞拉Maqueda A1酯卡伦Guarnizo A1 Rocio埃尔南德斯克莱尔A1 Maria Teresa Alba Isasi A1朱利安·巴斯克斯洛伦佐A1加布里埃尔·巴斯克斯洛伦佐A1安娜酯Baidez格雷罗州A1莫伊塞斯莫拉莱斯de la Prida A1玛丽亚canova伊涅斯塔A1朱迪斯·希门尼斯Veiga A1 Adelaida利昂·埃尔南德斯A1堡委拉斯开兹马林A1华金Zamarro Parra A1堡伊涅斯塔马丁内斯A1安娜莫拉莱斯Ortiz A1何塞台面式晶体管Lallana年2019 UL //www.ez-admanager.com/content/92/15_supplement/p3.2 - 069. -文摘AB目的:评估临床疾病活动停止后natalizumab疗法。背景:在多发性硬化症(MS) natalizumab (NTZ)撤军可能会导致炎症活动的“反弹”定义为严重的复发和MRI异常高的炎症活动。在我们中心两个不同的时间表与静脉注射metilprednisolone女士(IVMP)建立了以减少反弹的概率。设计/方法:回顾性分析患者NTZ在2年以上,2012年1月至2017年1月停止无效或安全原因。患者接受两个时间表NTZ-washout期限内(WP):表1(2012年- 2013年):3个月WP。1、2和3 IVMP克,每月分别。附表2(2014 - 2016):2个月WP。1和2分别IVMP克每个月。十天后每一计划,新的疾病修饰治疗(DMT)发起。临床和MRI评估(新/扩大T2和钆增强病灶)进行3日,6日,12日,NTZ-washout后24个月。结果:50例停用NTZ分析时期(68%的女性,平均年龄37.76 + /−10.88年,平均eds 3.7 + /−1.73)。新DMT fingolimod在77.6%。Annualized relapse rate (ARR) at 6th month was 0.32+/−0.84; MRI activity was observed in 25% of patients and “rebound” criteria only in 10% (n=5). ARR during WP was 0.1+/−0.7. No differences of clinical and MRI activity between both schedules was observed.Rebound was found in younger patients and was associated with higher ARR during the two years after NTZ and a higher presence of MRI activity at 3rd and 12th months, with no differences in EDSS scores after two years of follow-up. Neither pre-NTZ ARR nor new DMT was associated with rebound.Conclusions: Both IVMP schedules during WP was well tolerated and rebound was observed in only 10% of cases. In our study, IVMP could have reduced the possibility of rebound since in other series the proportion is higher.Disclosure: Dr. Fuentes Rumi has nothing to disclose. Dr. Cabrera Maqueda has nothing to disclose. Dr. Carreon Guarnizo has nothing to disclose. Dr. Hernandez Clares has nothing to disclose. Dr. Alba Isasi has nothing to disclose. Dr. Vázquez Lorenzo has nothing to disclose. Dr. Valero López has nothing to disclose. Dr. Baidez Guerrero has nothing to disclose. Dr. Morales de la Prida has nothing to disclose. Dr. Canovas Iniesta has nothing to disclose. Dr. Jimenez Veiga has nothing to disclose. Dr. León Hernández has nothing to disclose. Dr. Velaquez Marin has nothing to disclose. Dr. Zamarro Parra has nothing to disclose. Dr. Iniesta-Martínez has nothing to disclose. Dr. Morales Ortiz has nothing to disclose. Dr. Meca Lallana has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Almirall, Biogen, Genzyme, Merck Serono, Novartis, Roche and Teva.